Rising Pharmaceuticals, a subsidiary of Rising Pharma Holdings Inc., has announced the approval, launch, and immediate availability of Edetate calcium disodium injection, addressing a critical shortage of this vital therapy in the United States. This newly launched product is intended for the reduction of blood levels and depot stores of lead in cases of lead poisoning (both acute and chronic) and lead encephalopathy, in both pediatric and adult populations.

Ira Baeringer, the Chief Operating Officer of Rising Pharmaceuticals, stated, "The approval and introduction of Rising’s Edetate calcium disodium injection provides a crucial treatment option for individuals affected by lead poisoning, underscoring Rising’s dedication to alleviating supply shortages of essential medications for those in need."

Rising Pharmaceuticals boasts an expansive portfolio, with more than 182 commercialized generic medications and over 620 active SKUs, making it one of the largest generic pharmaceutical companies in the U.S. market. The company supplies nearly 9 billion doses of generic medicine annually to the market through its extensive global manufacturing network.

Edetate calcium disodium for injection is a prescription medication designed for treating acute and chronic lead poisoning in both adults and children. It's important to note that this injection should not be administered during anuria (lack of urine production), to patients with active renal disease, or to those with hepatitis.

Safety warnings are in place due to the potential for toxic effects from Edetate calcium disodium injection, which could even lead to fatality. While lead encephalopathy is relatively uncommon in adults, it occurs more frequently in pediatric patients where it might be overlooked. Pediatric patients with lead encephalopathy and cerebral edema are at risk of experiencing a dangerous increase in intracranial pressure after intravenous infusion, making the intramuscular route preferable. In cases where intravenous administration is necessary, rapid infusion should be avoided, and the recommended daily dosage must not be exceeded.

About Rising Pharmaceuticals: Rising Pharmaceuticals is a prominent supplier of generic and specialty-branded pharmaceuticals in the United States. The company focuses on various aspects of the product life cycle, including development, regulation, and commercialization, while partnering with a network of strategic CMO and CDO partners for manufacturing. The company is headquartered in New Brunswick, New Jersey. To learn more about the company, please visit www.risingpharma.com.

 

 

Report Abuse